Filtering by: MOUD
Nov
18
12:00 PM12:00
MOUD, Mutual Help Groups, 12-Step Programs, Implementation Science, Health Services Research, User Centered Design, Opioid use disorders

CDIAS PSMG: Wayne Kepner

“Beyond the False Dichotomy” Bridging the MOUD-Mutual Help Group Divide

Wayne Kepner, PhD, MPH
Stanford University

ABSTRACT:
A significant barrier to addressing the opioid crisis is the "false dichotomy" between two of our most effective strategies; medications for opioid use disorder (MOUD) and 12-step mutual help groups (MHG). MOUD is the most effective pharmacological treatment to reduce mortality, while MHGs provide invaluable access to peer-based recovery capital. A fragmented system of care exists despite evidence that combining these approaches yields superior outcomes. Facilities offering recovery support services are nearly eight times more likely to exclude MOUD patients, forcing individuals to navigate seemingly incompatible systems where they may be discouraged from MOUD use, increasing risks of treatment discontinuation and overdose.

View Event →
Apr
8
12:00 PM12:00
Buprenorphine, Harm Reduction, MOUD, Syringes Services Program

CDIAS PSMG: Andrea Jakubowski

Low Threshold Buprenorphine: What do we know and where do we go from here?

Andrea Jakubowski, MD, MS
Montefoire

ABSTRACT:
Over two decades into the opioid overdose crisis, buprenorphine remains underutilized and inaccessible to many people with opioid use disorder. Improving accessibility and utilization requires attention to where treatment is offered and how patients are treated once they enter care. In this presentation, Dr. Jakubowski will describe: 1) principles of low-threshold buprenorphine; 2) clinical and implementation data on syringes services program (SSP)-based buprenorphine programs; 3) early findings from Dr. Jakubowski’s NIDA K23 examining implementation of long-acting injectable buprenorphine in SSP and primary care clinics; 4) description and rationale of CTN-0155: Low-Threshold Buprenorphine Treatment at Syringe Services Programs: A Type I Hybrid Effectiveness-implementation Trial.

View Event →